CAR T Cell Therapy for Post-Transplant Lymphoproliferative Disorder After Solid Organ Transplantation: A Safe and Feasible Therapy for an Orphan Disease

Clin Lymphoma Myeloma Leuk. 2023 Oct;23(10):772-778. doi: 10.1016/j.clml.2023.05.007. Epub 2023 May 12.

¹ Bone Marrow Transplant and Cellular Therapy/Division of Hematology and Oncology, Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY. Electronic address: uroosa.ibrahim@mssm.edu.
² Department of Onconephrology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
³ Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
⁴ Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
⁵ Bone Marrow Transplant and Cellular Therapy/Division of Hematology and Oncology, Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY.

No abstract available

Keywords: Cellular therapy; Diffuse large B cell lymphoma; Liver transplant; Organ rejection; Renal transplant.

Publication types